– First and only FDA-approved orally administered microbiota-based therapeutic, validating Seres’ microbiome platform – – Phase 3 ECOSPOR III study demonstrated that 88% of treated individuals were recurrence-free at 8 weeks – – Opportunity to address prevention of recurrence of C. difficile infection in adults with rCDI, including first recurrence, following antibacterial treatment – – … [Read more…]

LAVAL, Quebec–(BUSINESS WIRE)–BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company working to better the lives of patients suffering from persistent cough, starting with the development of camlipixant (BLU-5937) for the treatment of refractory chronic cough (“RCC”), has announced the meeting and record dates for the special meeting of shareholders … [Read more…]

Strong clinical momentum continues in Phase 1/2 STAAR study in Fabry disease with 20 patients dosed in total. Dosed third patient in cohort 1 of Phase 1/2 CAR-Treg STEADFAST study for TX200 in HLA A2 mismatched kidney transplantation. Unveiled Nav1.7 target to treat chronic neuropathic pain as flagship program of wholly owned neurology epigenetic regulation … [Read more…]

MARSEILLE, France–(BUSINESS WIRE)–#ANKET–Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that it has filed a prospectus supplement with the Securities and Exchange Commission (“SEC”) relating to a new At-The-Market (“ATM”) program. Pursuant to this program, the Company may offer and sell to eligible investors (as described below) a total … [Read more…]

Highlights Net business wins in the quarter of $2,415 million; a net book to bill of 1.22. Closing backlog of $21.2 billion, an increase of 2.4% on quarter four 2022 or an increase of 8.4% on quarter one 2022. First quarter revenue of $1,978.6 million representing an increase of 4.0% on prior year revenue and … [Read more…]

Board of Directors approves quarterly cash dividend of $0.41 per share NEW YORK–(BUSINESS WIRE)–Pfizer Inc. (NYSE: PFE) today announced that its board of directors declared a $0.41 second-quarter 2023 dividend on the company’s common stock, payable June 9, 2023, to holders of the Common Stock of record at the close of business on May 12, … [Read more…]

MANHASSET, N.Y.–(BUSINESS WIRE)–It was a day of celebration and reflection as cardiac doctors, surgeons, nurses and therapists gathered at Sandra Atlas Bass Heart Hospital (SABHH) at North Shore University Hospital (NSUH) on April 26 to celebrate a medial milestone for the health system and region – more than 100 heart transplants have been performed since … [Read more…]

NEWTON, Mass.–(BUSINESS WIRE)–Diversified Healthcare Trust (Nasdaq: DHC) today announced that it will now host a conference call on Tuesday, May 9, 2023 at 11:00 a.m. Eastern Time, with President and Chief Executive Officer Jennifer Francis and Chief Financial Officer Richard Siedel discussing first quarter results. As previously announced, it will issue a press release containing … [Read more…]

Delivers revenue and EPS ahead of expectations, with total Invisalign® patients treated surpassing 15 million globally Completes May 13, 2021 $1 Billion Stock Repurchase Program Q1’23 total revenues of $943.1 million, increased 4.6% sequentially, and diluted net income per share of $1.14, non-GAAP diluted net income per share of $1.82 Q1’23 revenues were favorably impacted … [Read more…]

LEWISVILLE, Texas–(BUSINESS WIRE)–Orthofix Medical Inc. (NASDAQ:OFIX), a leading global spine and orthopedics company, today announced that it will release its first quarter 2023 financial results on Tuesday, May 9, 2023 after market close. The company will host a conference call and webcast to review results at 4:30 p.m. ET the same day. Interested parties may … [Read more…]